|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.5000 - 1.5000|
|52 Week Range||0.9500 - 3.5200|
|Beta (3Y Monthly)||3.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, is pleased to announce the appointment of its Vice President of Scientific Affairs, Dr. Robin A. Robinson, a respected authority on the development of breakthrough biomedical technologies, for which he was cited in 2018 as one of the top 100 innovators in medicine by The Medicine Maker. Notably, Dr. Robinson was appointed as Director of the Biomedical Advanced Research and Development Authority (BARDA), with an annual budget of $1.35 billion and a staff of 250 scientists and medical experts.
RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com) today announced the issuance of a new patent (U.S. Patent Number 10,376,658) allowing the Company’s novel medical device to now spray all varieties of tissues and cells, thus opening the door for its potential application in the regeneration of tissues and organs, beyond skin. “Just as we’ve used needles to inject drugs and vaccines in the 20th century, the syringe of tomorrow could be our patented SkinGun™, spraying a gentle healing mist of self-donated stem cells to regenerate human organs and tissue,” stated Dr. Ben Walthall, former Johnson & Johnson R&D Worldwide Director of Surgical Wound Care and Tissue Regeneration, and recently appointed RenovaCare Advisory Board member.
Dr. Walthall joins RenovaCare within weeks of the appointments of Dr. Rodney L. Sparks as Vice President of Intellectual Property and Dr. Roger Esteban-Vives to the position of Vice President of Research and Product Development. Among other duties, Dr. Walthall will provide ongoing support to Dr. Esteban-Vives in new product development and expanding the use of the RenovaCare technology platform for medical conditions beyond burns, such as reconstructive surgery and cosmetic applications, including acne scarring, wrinkles and tattoo removal.
“Just over six months ago, I made an equity investment of $15.5 million in RenovaCare to pursue human clinical trials for the SkinGun™ and explore the use of our cell spray technology for medical conditions beyond burns,” stated Mr. Harmel S. Rayat, the Company’s Chairman. Dr. Rodney Sparks is a respected intellectual property lawyer and technology licensing expert with decades of experience. He’s also a regarded scientist with postdoctoral training from the Johns Hopkins University and a research fellowship from the Mayo Clinic.
RenovaCare, Inc., (Symbol: RCAR; www.renovacareinc.com) developer of patented technologies for spraying a patient’s own stem cells onto burns and wounds for accelerated self-healing, is pleased to announce the appointment of Dr. Roger Esteban-Vives as Vice President of Research and Product Development. The appointment of Dr. Esteban-Vives follows a November 2018 equity financing of $15.5 million by Kalen Capital Corporation, wholly owned by Mr. Harmel S. Rayat, the Company’s Chairman.
“I’m more confident than ever in our mission to replace painful and costly skin grafting surgeries with an ultra-gentle healing mist of one’s own skin cells. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first.